89BIO

89bio is a clinical-stage biopharmaceutical company focused on rapidly advancing our lead product candidate, BIO89-100, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH). BIO89-100 is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It may be a differentiated FGF21 therapy, and we believe it has the potential to become a mainstay of therapy for NASH given its ability to address the key liver pathologies (steatosis and fibrosis) and underlying metabolic dysregulation in patients with NASH. We are also expanding the breadth of indications for BIO89-100 with an initial focus on severe hypertriglyceridemia (SHTG).